United States: Patent Cases Pending Before The Supreme Court (October Term)

Samsung Elecs. Co. v. Apple, Inc., No. 15-777

On March 21, 2016, the Supreme Court granted Samsung's petition for a writ of certiorari as to the following question:

Where a design patent is applied to only a component of a product, should an award of infringer's profits be limited to those profits attributable to the component?

The Supreme Court's first design patent case in 120 years arises out of the now well-known "rounded rectangle" design-patent litigation between Apple and Samsung. Below, a jury in the Northern District of California had found that Samsung infringed three of Apple's design patents and awarded Apple $399 million in damages.1 The Federal Circuit affirmed the jury's damages award as to infringement of the design patents.2

By contrast to utility patents, which protect "any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof,"3 design patents protect "any new, original and ornamental design for an article of manufacture."4

Samsung takes issue with the lower decisions that require Samsung to pay its entire profits on eleven smartphones for infringing three features of Apple's design patents.5 Samsung argues that its smartphones embody hundreds of thousands of patented features—not owned by Apple—and thus an entire profits damages model is inappropriate.6

The damages statute at issue is 35 U.S.C. § 289, which states:

Whoever during the term of a patent for a design, without license of the owner, (1) applies the patented design, or any colorable imitation thereof, to any article of manufacture for the purpose of sale, or (2) sells or exposes for sale any article of manufacture to which such design or colorable imitation has been applied shall be liable to the owner to the extent of his total profit, but not less than $250, recoverable in any United States district court having jurisdiction of the parties. Nothing in this section shall prevent, lessen, or impeach any other remedy which an owner of an infringed patent has under the provisions of this title, but he shall not twice recover the profit made from the infringement.

Apple argued, in its brief in opposition to Samsung's petition, that the text of Section 289 is clear, and that the Federal Circuit's application of the total-profits rule is well supported by the statute's history and purpose.7

In its merits brief, Samsung argues that the Federal Circuit's total-profits rule conflicts with the text, history, and purpose of the statute.8

Samsung's textual argument is that Section 289 "limits recoverable total profit to that attributable to the 'article of manufacture' to which an infringing design is 'applied.' Such an article need not be the entire product as sold; many discrete 'articles of manufacture' may be combined into such a product."9 Samsung also notes that Section 289 limits recoverable total profit to that "made from the infringement."10 In other words, that limitation precludes an award of profit not attributable to infringement of the patented design.

Samsung's historical argument is that Congress enacted the statute to ensure that patentees recover more than nominal damages for products where the design was the principal feature—articles such as decorative wallpaper or carpet.11 Samsung argues that this rationale makes no sense for complex products like smartphones that embody hundreds of thousands of patents.12

Samsung's statutory purpose argument is that the Federal Circuit's automatic total profits rule would have disastrous consequences to innovation, competition, and small business.13

If the Supreme Court agrees with Apple, design patent infringement litigation should become a significant focus because of the amount of damages and the ease of proof of those damages. If the Supreme Court agrees with Samsung, the recent increase in design patent infringement litigation will likely be but a flash in the pan.

SCA Hygiene Products Aktiebolag v. First Quality Baby Products, LLC, No. 15-927

On May 2, 2016, the Supreme Court granted SCA Hygiene's petition for a writ of certiorari on the following question: "Whether and to what extent the defense of laches may bar a claim for patent infringement brought within the Patent Act's six-year statutory limitations period, 35 U.S.C. § 286."

Section 286 of the Patent Act provides as follows: "Except as otherwise provided by law, no recovery shall be had for any infringement committed more than six years prior to the filing of the complaint or counterclaim for infringement in the action."14 The Federal Circuit has held that, in addition to Section 286, the equitable doctrine of laches is also a cognizable defense to patent infringement, further potentially shortening the six-year damages limitation period.15

Petitioner SCA argues in its petition for certiorari and in its opening merits brief that the plain text of Section 286 does not authorize such a shortening of the six-year period for infringement damages.16 In doing so, SCA relies on recent Supreme Court precedent from the Court's copyright jurisprudence—Petrella v. Metro-Goldwyn-Mayer, Inc., 134 S.Ct. 1962 (2014)—to argue that laches, a doctrine historically developed by courts of equity, is not available as a defense to a claim for legal relief which is governed by a statute of limitations.17 In Petrella, the Court held that laches could not be used to shorten the three-year limitations period under the Copyright Act because this would, in effect, substitute the judgment of a district court for that of Congress.18 Laches, the Court explained, historically applied to "claims of an equitable cast for which the Legislature has provided no fixed time limitation."19 SCA argues that Petrella is controlling, and that the Federal Circuit's basis for finding a damages-barring laches defense within the Patent Act20 is inadequate.21

By contrast, respondent First Quality argues (in its opposition to SCA Hygiene Products' petition for certiorari22) that the Federal Circuit has for decades held that 35 U.S.C. § 282 includes a laches defense, and that the laches defense in Section 282 bars patentee from both legal and equitable relief.23 In addition, First Quality argues that, even before the 1952 Patent Act, courts routinely applied the doctrine of laches to bar both legal and equitable relief to patent infringement claims, and that Congress incorporated this judicial understanding into the statute.24

If the Supreme Court agrees with SCA, a patentee's unreasonable delay in bringing suit will no longer be a basis for barring or limiting damages for patent infringement within the six-year period prescribed in § 286. Either way, it seems clear that the same delay can affect injunctive relief and, in appropriate cases, may contribute to an equitable estoppel defense, which, if successful, would preclude all relief.

Life Technologies Corp. v. Promega Corp., No. 14-1538

On June 27, 2016, the Supreme Court granted Life Technologies' petition for a writ of certiorari to answer the following question: "Whether the Federal Circuit erred in holding that supplying a single, commodity component of a multi-component invention from the United States is an infringing act under 35 U.S.C. § 271(f)(1), exposing the manufacturer to liability for all worldwide sales."25

35 U.S.C. § 271(f)(1) provides:

Whoever without authority supplies or causes to be supplied in or from the United States all or a substantial portion of the components of a patented invention, where such components are uncombined in whole or in part, in such manner as to actively induce the combination of such components outside the United States in a manner that would infringe the patent if such combination occurred within the United States, shall be liable as an infringer.

Life Technologies assembles genetic testing kits that generate DNA profiles. The kits contain a number of components, including: (1) a primer mix; (2) Taq polymerase; (3) a PCR reaction mix including nucleotides; (4) a buffer solution; and (5) control DNA. Together, these components are capable of amplifying the DNA being studied, a process necessary to obtain a detectable amount of DNA for analysis.

Life Technologies manufactures one component of its kits in the U.S., the Taq polymerase, which it ships overseas to its facility in the United Kingdom for assembly with the other kit components and worldwide sale. It is undisputed that Taq polymerase is not especially made or especially adapted for use in the invention at issue.

Promega sued its field-limited licensee Life Technologies in 2010, alleging that Life Technologies had infringed a DNA replication patent by selling its kits into unlicensed fields. Promega sought damages for worldwide sales.

At trial, the jury returned a verdict for Promega, found that Life Technologies' infringement was willful, and awarded damages for all worldwide sales. The district court then granted judgment as a matter of law to Life Technologies, holding that Promega had failed to present sufficient evidence to sustain a jury verdict under Section 271(f)(1). The district court provided two main reasons for its decision: (1) Promega did not present any evidence that Life Technologies induced another party to combine any components outside the U.S. in an infringing manner (i.e., Life Technologies did all the combining itself); and (2) Life Technologies manufactures only a single component in the U.S., which is insufficient to meet Section 271(f)'s requirement that "all or a substantial portion" of the components be supplied from the U.S.

A split Federal Circuit reversed.26 The majority held that a party could induce itself within the meaning of Section 271(f)(1), and further, that a party may be liable under 271(f)(1) for supplying a single component for combination outside the U.S.22 With respect to the latter point, the majority reasoned that "substantial" in the statute means "important" or "essential," and not merely significant by volume or number.27

The Supreme Court granted certiorari only to address the second of the Federal Circuit's holdings. On that issue, Life Technologies argued in its petition that "a substantial portion" in Section 271(f)(1) refers to the quantity, not the subjective importance or relative significance, of the components supplied.28 Thus, according to Life Technologies, to meet Section 271(f)(1)'s "substantial portion" requirement, the portion must be a "large" or "considerable" quantity, not just a single component that is qualitatively "important."29 Life Technologies bases its argument, in part, on the difference between Congress' use of the plural "components" in Section 271(f)(1) and Congress' use of the singular "component" in Section 271(f)(2).30 Section 271(f)(2) provides a basis for infringement liability for the supply of a single component so long as it is "especially made or especially adapted for use in the invention and not a staple article or commodity of commerce" (which stricture prevents the application of Section 271(f)(2) to Life Technologies).31

Promega, in its opposition to Life Technologies' petition, argued that the Supreme Court should not adopt a bright-line rule that a single component can never be the basis for liability under Section 271(f)(1).32 According to Promega, "[s]ubstantiality is a fact question that requires a case-specific analysis of what is being supplied from the United States and its relationship to the patented invention across multiple dimensions, including not only quantity but also relative importance."33 A fact-specific inquiry properly gives courts flexibility and, in this particular case, the polymerase that Life Technologies supplied from the U.S. is a major component of the infringing kits.34

Petitioners' opening brief on the merits is due September 1, 2016.

Footnotes

1 E.g., Petition for a Writ of Certiorari at 17, Samsung Elecs. Co., Ltd. v. Apple Inc. (No. 15-777) ("Samsung Petition"). The jury also awarded $382 million in damages attributable to trade dress dilution and $149 million in damages attributable to utility patent infringement. Id. Those issues and damages awards are not the subject of this case.

2 Samsung Petition at 18.

3 35 U.S.C. § 101.

4 35 U.S.C. § 171.

5 Brief for Petitioners at 1, Samsung Elecs. Co., Ltd. v. Apple Inc. (No. 15-777) ("Samsung Brief").

76Id.

7 Brief in Opposition at 25, Samsung Elecs. Co., Ltd. v. Apple Inc. (No. 15-777) ("Apple Opposition to Samsung Petition").

8 Samsung Brief at 1.

9 Id. at 24–25.

10 Id.

11 Id.

12 Id.

13 Id. at 26. 

14 35 U.S.C. § 286.

15 E.g., A.C. Aukerman Co. v. R.L. Chaides Constr. Co., 960 F.2d 1020 (Fed. Cir. 1992) (en banc).

16 Petition for a Writ of Certiorari at, e.g., 14, SCA Hygiene Prods. Aktiebolag v. First Quality Baby Prods., LLC, (No. 15-927) ("SCA Hygiene Prods. Petition"); Brief for Petitioners at 5, SCA Hygiene Prods. Aktiebolag v. First Quality Baby Prods., LLC, (No. 15-927) ("SCA Hygiene Prods. Brief").

17 SCA Hygiene Prods. Brief at 14.

18 Petrella, 134 S.Ct. at 1967–68.

19 Id. at 1973.

20 The relevant text is as follows: "The following shall be defenses in any action involving the validity or infringement of a patent and shall be pleaded: (1) Noninfringement, absence of liability for infringement or unenforceability." 35 U.S.C. § 282(b).

21 SCA Hygiene Prods. Brief at 4, 31.

22 As of this writing, First Quality Baby Products has not yet submitted its merits briefing. Many of its arguments, including, for example, its argument that Congress codified a laches defense in § 282, will likely be substantially similar if not the same in its merits briefing.

23 Brief in Opposition at 1–2, SCA Hygiene Prods. Aktiebolag v. First Quality Baby Prods., LLC, (No. 15-927).

24 Id. at 15.

25 The full list of petitioners is Life Technologies Corp., Invitrogen IP Holdings, Inc., and Applied Biosystems, LLC. 

26 Promega Corp. v. Life Techs. Corp., 773 F.3d 1338 (Fed. Cir. 2014).

27 Id. at 1351–53.

28 Id. at 1353.

29 Petition for a Writ of Certiorari at 3–4, 22–23, Life Techs. Corp. v. Promega Corp. (No. 14-1538) ("Life Tech Petition"); see also Supplemental Brief of Petitioners at 2, Life Techs. Corp. v. Promega Corp. (No. 14-1538) ("Life Tech Supp. Brief").

30 Life Tech Petition at 23.

31 Id. at 4. 

32 Id.

33 Brief in Opposition at 1–2, Life Techs. Corp. v. Promega Corp. (No. 14-1538).

34 Id. at 26.

35 Id. at 2. 

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions